Table 3.
authors | Patients (n) |
Technique (%) |
Volume (ml) |
Dose (Gy) |
Follow-up (months) |
Local control (%) |
Late toxicity (%) |
---|---|---|---|---|---|---|---|
Goldsmith et al., 1994 | 117 | CRT | NA | 54 | 40 | 89 at 5 and 77 at 10 years | 3.6 |
Maire et al., 1995 | 91 | CRT | NA | 52 | 40 | 94 | 6.5 |
Peele et al., 1996 | 42 | CRT | NA | 55 | 48 | 100 | 5 |
Condra et al.,1997 | 28 | CRT | NA | 53.3 | 98 | 87 at 15 years | 24 |
Connell et al., 1999 | 54 | CRT | NA | 54 | 55 | 76 at 5 years | 19 |
Maguire et al., 1999 | 26 | CRT | NA | 53 | 41 | 8 at 8 years | 8 |
Nutting et al., 1999 | 82 | CRT | NA | 55-60 | 41 | 92 at 5 and 83 at 10 years | 14 |
Vendrely et al., 1999 | 156 | CRT | NA | 50 | 40 | 79 at 5 years | 11.5 |
Dufour et al., 2001 | 31 | CRT | NA | 52 | 73 | 93 at 5 and 10 years | 3.2 |
Pourel et al., 2001 | 28 | CRT | NA | 56 | 30 | 95 at 5 years | 4 |
Mendenhall et al., 2003 | 101 | CRT | NA | 54 | 64 | 95 at 5, 92 at 10 and 15 years | 8 |
Debus et al., 2001 | 189 | FSRT | 52.5 | 56.8 | 35 | 97.3 | 1.6 |
Jalali et al., 2002 | 41* | FSRT | 17.9 | 55 | 21 | 100 | 12.1 |
Lo et al., 2002 | 18* | FSRT | 8.8 | 54 | 30.5 | 93.3 | 5 |
Torres et al., 2003 | 77* | FSRT | 16.1 | 48.4 | 24 | 97.2 | 5.2 |
Selch et al., 2004 | 45 | FSRT | 14.5 | 56 | 36 | 100 at 3 years | 0 |
Milker-Zabel et al., 2005 | 317* | FSRT | 33.6 | 57.6 | 67 | 90.5 at 5 and 89 at 10 years | 8.2 |
Henzel et al., 2006 | 84 | FSRT | 11.1 | 56 | 30 | 100 | NA |
Brell et al., 2006 | 30 | FSRT | 11.3 | 52 | 50 | 93 at 4 years | 6.6 |
Hamm et al., 2008 | 183 | FSRT | 27.4 | 56 | 36 | 97 at 5 years | 8.2 |
Litré et al., 2009 | 100 | FSRT | NA | 45 | 33 | 94 at 3 years | 0 |
Metellus et al., 2010 | 47 | FSRT | 12.6 | 52.9 | 82.8 | 98 at 5 and 96 at 10 years | 2.6 |
Tanzler E et al., 2010 | 144** | FSRT | NA | 52.7 | 96 | 97 at 5 and 96 at 10 years | 7 |
CRT, conformal 3-D radiotherapy; FSRT, fractionated stereotactic radiotherapy
*Series include some patients with intracranial meningiomas
** 41 patients received CRT